

Sunday, April 26th, 2026

13:00-18:30 Registration Desk Open

16:00 Welcome

16:15-17:15 Keynote: James Gulley, NIH – *NeoAdjuvant Trial Design*

17:15-21:00 Reception and Poster Session

Monday, April 27th, 2026

07:30-18:30 Registration Desk Open

07:30-8:30 Welcome and registration delegates with breakfast, coffee/tea.

8:30-9:30 Keynote: Nathalie Agar, Harvard University - *spatial imaging, mass spec imaging, and metabolomics*

9:30-10:30 Session #1: Clinical Trials I (Chairs Nino Chiocca and Alan Melcher)

9:30-9:50 - Thomas Heineman, Oncolytics Biotech "*Clinical Efficacy and Future Development of Pelareorep: A Novel Reovirus with Demonstrated Activity in Multiple Gastrointestinal Cancers*"

9:55-10:15 - Praveen Bommareddy, Replimune, "*Next generation Oncolytic immunotherapy for cancer treatment*"

10:20-10:30 - Shruthi Naik, Mayo Clinic "*Combination systemic oncolytic immunotherapy in patients with advanced neuroendocrine carcinoma*"

10:35-10:50 XDemics Inc – *A Revolutionary Cell Culture Format*

10:50-11:15 Morning Coffee Break

11:15-12:50 Session #1: Clinical Trials I (continued) (Chairs Nino Chiocca and Alan Melcher)

11:15-11:35 - James Burke, "*Cretostimogene (aka CG0070) for non-muscle invasive bladder cancer – a clinical update*"

11:40-12:00 - William Jia, Virogin "*Oncolytic virotherapy: A potential cornerstone for all IO modalities*"

12:05-12:25 - Francesca Barone, Candel, "*CAN-2409: locally delivered viral immunotherapy for solid tumors*"

12:30-12:50 - Evanthia Galanis, Mayo Clinic "*Phase I/II trial of measles virus infected adipose tissue derived mesenchymal stem cells in patients with recurrent ovarian cancer*"

12:55-14:00 Lunch – provided

14:00-15:20 Session #2: Combination Therapies (Chairs Stephen Russell and Sam Rabkin)

14:00-14:20 - Kah-Whye Peng, Vyriad "*A Phase 1 Clinical Trial to Evaluate Intravenous VSV-IFN β -NIS in Combination with Cemiplimab and Ipilimumab for Relapsed Peripheral T-Cell Lymphoma*"

14:25-14:35 - Samuel Rabkin, Harvard "*Oncolytic HSV Synergizes with DNA-PKcs Inhibition to Treat Glioblastoma*"

14:40-14:50 - Richard Vile, Mayo Clinic "*Oncolytic Virus-Specific T Cell Receptor Activation Enhances CAR T Cell Potency, Persistence and Anti-Tumour Efficacy*"

14:55-15:05 - Candelaria Gomez-Manzano, MD Anderson *"Epigenetic Modulation of P300/CBP Boosts Delta-24-RGD-Induced Immune Cell Recruitment in Diffuse Midline Glioma"*

15:10-15:20 - Tomoko Fujiyuki, Teikyo University *"Immune responses elicited by rMV-SLAMblind oncolytic therapy exert a synergistic effect on the cancer therapy"*

15:20-16:00 Afternoon Coffee Break

16:00-17:30 Session #3: Mechanism of Action (Chairs Brian Lichty and Tommy Alain)

16:00-16:20 - Chae-ok Yun, GeneMedicine *"Intranasal Nanoplatform and Potent Oncolytic Adenovirus Therapy for Glioblastoma"*

16:25-16:35 - Frederic Tangy, Oncovita *"Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I-driven cancer immunotherapy"*

16:40-16:50 - Leandro Silva da Costa, Aarhus University *"Oncolytic VSVdeltaM51 Activates NLRP1 Inflammasome Signaling While Wild-Type VSV Evades Innate Restriction"*

16:55-17:05 - Bangxing Hong, Augusta University *"Beta-blocker mitigates perivascular macrophage mediated immunosuppression during oncolytic herpes virotherapy"*

17:10-17:20 - Norimitsu Kadowaki, Kagawa University *"The Abscopal Effect of Oncolytic HSV-1 Requires TLR9-Driven Plasmacytoid Dendritic Cell Activation"*

17:30-21:00 Poster session, buffet dinner and drinks

Tuesday, April 28th, 2026

08:00-18:30 Registration Desk Open

08:00-9:00 Welcome and registration delegates with breakfast, coffee/tea.

9:00-10:15 Session #4: Clinical Trials II (Chairs Evanthis Galanis and Kah-Whye Peng)

9:00-9:20 - James Burke, Kalivir *"VET3-TGI: Interim Phase I Clinical data in Solid Tumours"*

9:25-9:45 - Akseli Hemminki, TILT *"Which is more effective clinically, intravenous or intratumoral delivery? Data from circa 100 patients treated with oncolytic adenovirus TILT-123"*

9:50-10:00 - Frederick Lang, MD Anderson *"Phase I Trial of Bone Marrow-Derived Mesenchymal Stem Cells Carrying Delta-24-RGD Delivered via Endovascular Selective Intra-arterial (ESIA) Infusion in Recurrent Glioma: Initial Report"*

10:15-10:45 Morning Coffee Break

10:45-12:30 Session #5: Novel Platforms and Payloads (Chairs Grant McFadden and John Bell)

10:45-11:05 - Adam Schieferecke, Vivere *"CRISPR-Guided Evolution of Improved Delivery Systems for Genetically Encoded Immunotherapies"*

11:10-11:30 - Nanhai Chen, ViroMissile *"A Systemically Deliverable Vaccinia-Based Oncolytic Virus, VIR106, Demonstrates Potent Antitumor Activity After a Single Intravenous Dose"*

11:35-11:55 - Stephen Russell, Vyriad *"Oncolytic Virotherapy Expands and Reprograms T Cells into CAR-T Cells Within the Tumor Microenvironment"*

12:00-12:10 - Tommy Alain, CHEO *"Oncolytic reovirus as an oral cancer immunotherapy"*

12:15-12:25 - Karen Mossman, McMaster University *"HLA-matched humanized mouse model to study pancreatic ductal adenocarcinoma"*

12:30-14:00 Lunch – provided

14:00-15:30 Session #6: Tumour Microenvironment (Chairs Nori Kasahari and Carolina Ilkow)

14:00-14:20 - Nino Chiocca, Harvard *“Persistent T cell Activation and Cytotoxicity against Human Glioblastoma Following Single Oncolytic Virus Treatment”*

14:25-14:45 - Alan Melcher, The Institute of Cancer Research *“Impact of Anti-viral vs Anti-tumour CD8 response on treatment with HSV”*

14:50-15:00 - Liang Deng, Rockefeller *“Intravesical Recombinant MVA Therapy Induces Local and Systemic Antitumor Immunity and Memory in an Orthotopic Murine Bladder Cancer Model”*

15:05-15:15 - Elizabeth Appleton, ICR UK *“Intratumoural oncolytic HSV-1 reshapes the local and systemic immune landscape through CD8+ T cell reprogramming”*

15:20-15:30 - Duong Nguyen, Calidi *“A Next- Generation Systemic Platform for Tumor-Localized Expression of T-Cell Engagers and Immune Activator”*

15:35-15:45 - Yong Tang, Guangxi Medical University Cancer Hospital *“Mesenchymal Stem Cells Delivering IL-33 Oncolytic Vaccinia Virus Enhance Antitumor Effects and Overcome PD-1 Inhibitor Resistance in Bladder Cancer”*

15:45-19:00 Free time for Delegates

19:00-23:30 Banquet Dinner - provided, at Harpa Conference Centre

Wednesday, April 29th, 2026

08:00-13:00 Registration Desk Open

08:00-8:45 Welcome and registration delegates with breakfast, coffee/tea

8:45-9:45 Keynote: Klaus Pantel, Medical Center Hamburg-Eppendorf (UKE) “Using Liquid Biopsies to Monitor Clinical Trials”

9:45-10:45 Session #7: Biomarkers of Clinical Response (Brian Lichty and Alan Melcher)

9:45-10:05 - Richard Trauger, Oncolytics Biotech *“Innate, an -viral and an -tumor biomarkers associated with clinical responses to pelareorep”*

10:10-10:20 - Juan Fueyo, MD Anderson *“Integrative TCR-seq/Spatial transcriptomics studies correlate with survival in virotherapy-treated gliomas”*

10:25-10:35 - Linus Kloker, University Hospital Tübingen *“Case series: Off-label treatment with T-VEC as an additive immunovirotherapy for aggressive NUT-carcinomas”*

10:40-10:50 - Talia Biran, Cornell *“Long Term Survival with Oncolytic Viral therapy: Final results of a Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma”*

10:55-11:20 Morning Coffee Break

11:20-12:35 Session #8: Young Investigators Talks (Chair Carolina Ilkow and Tommy Alain)

11:20-11:30 - Victor Arias, University of Helsinki “Neutralizing antibodies as biomarkers and functional effectors in TILT-123 oncolytic adenovirus therapy”
11:35-11:45 - Iker Ausejo Mauleon, University of Navarra “The combination of Delta-24-RGD and TIM-3 blockade enhances oncolytic virotherapy in diffuse midline glioma”
11:50-12:00 - Kyla Boyd, Mayo Clinic “Improved iRNA-LNP Therapeutic Performance Through 5’UTR-Restricted MicroRNA Detargeting”
12:05-12:15 - Tine Deconinck, KU Leuven, “Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes”
12:20-12:30 - Ryo Ikushima, Kyoto Prefectural University of Medicine “A Potent and Selective PHOX2B Promoter–Driven Oncolytic Adenovirus for Targeted Neuroblastoma Therapy”

12:35 Closing Remarks and Farewell